Probably already been posted somewhere, but a few analysts are quoting up to $23 us for MESO in the next 12 months. Considering its history of strong spikes, lets see if history repeats. This from last week
In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Mesoblast Ltd (NASDAQ: MESO), with a price target of $16. The company’s shares closed yesterday at $6.63.
According to TipRanks.com, Breidenbach is a 4-star analyst with an average return of 10.1% and a 46.0% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Alpine Immune Sciences Inc, and Global Blood Therapeutics.
Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $18, a 171.5% upside from current levels. In a report issued on September 18, H.C. Wainwright also maintained a Buy rating on the stock with a $17 price target.
MSB trading, page-1803
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.070(6.45%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.20 | $1.11 | $20.88M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 59978 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 34019 | 3 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.070 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.20 | $1.12 | 3733217 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| MSB (ASX) Chart |